Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators

Rebecca P. Sumner, Hongwei Ren, Brian J. Ferguson, Geoffrey L. Smith

Article Info

Article history:
Received 25 April 2016
Received in revised form 30 July 2016
Accepted 1 August 2016
Available online 17 August 2016

Keywords:
Vaccinia virus
Immunogenicity
NF-κB inhibitor
IRF3 inhibitor
Vaccine efficacy

Abstract

Vaccinia virus (VACV)-derived vectors are popular candidates for vaccination against diseases such as HIV-1, malaria and tuberculosis. However, their genomes encode a multitude of proteins with immunomodulatory functions, several of which reduce the immunogenicity of these vectors. Hitherto only limited studies have investigated whether the removal of these immunomodulatory genes in combination can increase vaccine efficacy further. To this end we constructed viruses based on VACV strain Western Reserve (WR) lacking up to three intracellular innate immunomodulators (N1, C6 and K7). These genes were selected because the encoded proteins had known functions in innate immunity and the deletion of each gene individually had caused a decrease in virus virulence in the murine intranasal and intradermal models of infection and an increase in immunogenicity. Data presented here demonstrate that deletion of two, or three of these genes in combination attenuated the virus further in an incremental manner. However, when vaccinated mice were challenged with VACV WR the double and triple gene deletion viruses provided weaker protection against challenge. This was accompanied by inferior memory CD8+ T cell responses and lower neutralising antibody titres. This study indicates that, at least for the three genes studied in the context of VACV WR, the single gene deletion viruses are the best vaccine vectors, and that increased attenuation induced by deletion of additional genes decreased immunogenicity. These data highlight the fine balance and complex relationship between viral attenuation and immunogenicity. Given that the proteins encoded by the genes examined in this study are known to affect specific aspects of innate immunity, the set of viruses constructed here are interesting tools to probe the role of the innate immune response in influencing immune memory and vaccine efficacy.

1. Introduction

The poxvirus family is a diverse group of dsDNA viruses that replicate in the cytoplasm of infected cells. The potential use of this family, particularly the well-characterised vaccinia virus (VACV) strains, as vaccine vectors has been under investigation since the 1980s [1]. VACV has many features that make it attractive for this use: a large capacity for foreign gene expression, relative ease of manipulation, and, importantly, induction of strong innate and memory immune responses, including both cellular and humoral arms [2]. Much research has focused on modified virus Ankara (MVA) and NY-VAC because of their severe attenuation, and, at least for MVA, the inability to replicate in most mammalian cells. These vectors are safe even in immunocompromised hosts [3,4], which is of particular importance for vaccination against diseases such as HIV-1, malaria and tuberculosis [2]. There is still a need to improve the immunogenicity of these vectors, particularly because large viral doses, repeated vaccination or prime-boost regimes are required to achieve adequate correlates of protection [5].

The host antiviral innate immune response provides a strong selective pressure and, consequently, viruses have evolved a plethora of mechanisms to counteract its effects. Engagement of viral components with innate immune receptors activates transcription factors including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and interferon (IFN) regulated factors (IRF)-3/7 that coordinate the production of pro-inflammatory cytokines, chemokines and type I IFNs (reviewed in [6,7]). Importantly this pro-inflammatory milieu attracts professional antigen presenting cells to the site of infection, providing an important link to the adaptive immune response and the subsequent establishment of immune memory.
VACV dedicates between one third and one half of its genome to dampening host innate responses (reviewed in [6]). For example, nine intracellular NF-κB inhibitors have been identified and there is evidence that more remain to be discovered [8]. In addition, VACV encodes numerous IRF-3/7 inhibitors and multiple mechanisms to counteract the actions of IFNs [6]. The mechanisms by which innate immunity impacts successful vaccine design remain incompletely understood. Importantly, recent data have demonstrated that the deletion of several VACV immunomodulatory genes individually enhances the immunogenicity of these vectors (reviewed in [6,9]). Examples of such genes include the NF-κB inhibitor N1 [10], the IRF-3/7 inhibitor C6 [11,12] and the dual NF-κB and IRF-3/7 inhibitor K7 [13] and Ren et al., unpublished data). Proteins N1 and K7 have Bcl-2 folds [14,15] and C6 is predicted and IRF-3/7 inhibitor K7 ([13] and Ren et al., unpublished data).

Some studies have investigated the effect of deleting multiple immunomodulatory genes from VACV vectors but so far have not included an in-depth comparison of single gene deletions in isolation versus deletion of genes in combination [13,20,21]. These comparisons have also not always included challenge experiments, instead measuring aspects of immunological memory that may correlate with immune protection. This study therefore tested whether the immunogenicity of VACV could be improved further by deleting three intracellular innate immunomodulators in combination (encoded by genes N1L, C6L and K7R) from VACV strain Western Reserve (WR). These immunomodulators were selected because their function in innate immunity was known, and because deletion of each of these genes in isolation from VACV WR increased immunogenicity, but decreased virulence. This study shows that deletion of these three genes did not affect VACV growth in vitro, but led to sequential attenuation of the virus in two in vivo models. In challenge models, despite each individual gene deletion enhancing immunogenicity, a virus lacking all three genes was a poorer vaccine, accompanied by inferior memory T cell responses and lower neutralising antibody titres. This illustrates how the design of vaccines for optimal immunogenicity must consider how the degree of attenuation impacts on the induction of immunological memory.

2. Materials and methods

2.1. Cells, viruses and mice

VACV and Escherichia coli guanylphosphoribosyl transferase (Ecogp) gene fused in-frame with the enhanced green fluorescent protein (EGFP) gene under the control of the VACV 7.5 K promoter. Revertant VACV strains were described previously. Female mice Balb/c and C57/B6 were described previously. Female mice Balb/c and C57/B6 were described previously.

Female BALB/c mice (n = 5, 6–8 weeks old) were infected intranasally (i.n.) with 5 × 10^7 p.f.u. of purified VACV strains. VACV was purified from cytoplasmic extracts of infected cells by two rounds of sedimentation through 36% (w/v) sucrose at 32,900g for 80 min. Viruses were resuspended in 10 mM Tris-HCl pH 9. Virus used for infections was diluted in phosphate-buffered saline containing 1% bovine serum albumin and the titre of the diluted virus that was used to infect mice was determined by plaque assay on the day of infection. Mice were monitored daily to record body weight and signs of illness as described [26,27]. Female C57BL/6j mice (n = 5, 6–8 weeks old) were inoculated intradermally (i.d.) in both ear pinnae with 10^7 p.f.u. and the resulting lesions were measured daily as described [28,29]. For the challenge experiments, mice that had been inoculated i.n. were challenged 6 weeks later and mice that had been inoculated i.d. were challenged 4 weeks later, i.n., with 5 × 10^7 p.f.u. of wild-type VACV WR.

2.2. Construction of Western Reserve recombinant viruses

Viruses were constructed using the transient dominant selection method [22] as described [18], using vAN1 [17] as a starting point and plasmids Z11A6C [18] and pSjH7-AK7 [19] to delete C6L and K7R respectively. Z11 is a pCl-derived plasmid containing the Escherichia coli guanylylphosphoribosyl transferase (Ecogpt) gene fused in-frame with the enhanced green fluorescent protein (EGFP) gene under the control of the VACV 7.5 K promoter. Revertant viruses were constructed by replacing the deleted genes in their natural loci using plasmids Z11C6Rev [18] and pSjH7-K7 [19]. The genotype of resolved viruses was analysed by PCR following proteinase K-treatment of infected BSC-1 cells using primers that anneal to the flanking regions of N1L, C6L and K7R [17–19]. Infectious virus titres were determined by plaque assay on BSC-1 cells.

2.3. SDS-PAGE and immunoblotting

Infected BSC-1 cells were lysed in a cell lysis buffer containing 50 mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X100, 0.05% (v/v) NP40 supplemented with protease inhibitors (Roche). Samples were boiled for 5 min and then subjected to SDS-PAGE. Primary antibodies were from the following sources: mouse anti-α-tubulin (Upstate Biotech), mouse anti-D8 mAb AB11.1 [23], rabbit-anti-N1 polyclonal antiserum [17], rabbit-anti-C6 polyclonal antiserum [18] and rabbit-anti-K7 polyclonal antiserum [24]. Primary antibodies were detected with goat-anti-mouse/rabbit IRDye 800CW infrared dye secondary antibodies and membranes were imaged using an Odyssey Infrared Imager (LI-COR Biosciences).

2.4. Plaque size analysis

BSC-1 cells were inoculated at approximately 50 plaque forming units (p.f.u.) per well of a 6-well plate and stained with crystal violet 3 days later [18]. The sizes of 20 plaques per well were measured using Axiovision acquisition software and a Zeiss AxioVert. A1 inverted microscope as described [25].

2.5. Murine intranasal and intradermal models of infection

Virus was resuspended in 10 mM Tris-HCl pH 9. Virus used for infections was diluted in phosphate-buffered saline containing 1% bovine serum albumin and the titre of the diluted virus that was used to infect mice was determined by plaque assay on the day of infection. Mice were monitored daily to record body weight and signs of illness as described [26,27]. Female C57BL/6j mice (n = 5, 6–8 weeks old) were inoculated intradermally (i.d.) in both ear pinnae with 10^7 p.f.u. and the resulting lesions were measured daily as described [28,29]. For the challenge experiments, mice that had been inoculated i.n. were challenged 6 weeks later and mice that had been inoculated i.d. were challenged 4 weeks later, i.n., with 5 × 10^7 p.f.u. of wild-type VACV WR.

2.6. Intracellular cytokine staining

Splenocytes were prepared as described [10] and incubated for 4 h with a C57BL/6–specific CD8+ VACV peptide B820–27 [30] or a negative control CD8+ VACV peptide specific for BALB/c mice, E3140–148 [31] at a final concentration of 0.1 μg/ml. After 1 h Golgi stop (BD Biosciences) was added and the cells were incubated for a further 3 h. Cells were then stained for CD8 and either IFNγ or TNFα and analysed by flow cytometry [10].

2.7. 51Cr release cytotoxic assay

Cytotoxic T lymphocyte (CTL) activity was assayed with a standard 51Cr-release assay using VACV-infected EL-4 cells as targets, as described [32]. The percentage of specific 51Cr-release was calculated as specific lysis = [(experimental release – spontaneous release)/(total detergent release – spontaneous release)] × 100. The spontaneous release values were always <5% of total lysis.
2.8. IMV plaque reduction neutralisation assay

The neutralising titre of anti-VACV antibodies was calculated by plaque assay on BSC-1 cells as described [10]. Neutralisation dose 50 (ND50) values represent the reciprocal of the serum dilution giving 50% reduction in plaque number compared with virus incubated without serum.

2.9. Serum antibody titration by ELISA

The binding of serum antibodies to VACV-specific epitopes was measured by enzyme-linked immunosorbent assay (ELISA) using plates coated with lysates of VACV strain WR-infected cells that had been treated with ultraviolet light and psoralen to inactivate VACV infectivity as described [33,34]. Plates coated with bovine serum albumin were used as a negative control. IgG end-point titres were defined as the reciprocal serum dilutions giving twice the average optical density values obtained with bovine serum albumin.

2.10. Statistical analysis

Data were analysed using an un-paired Student’s t-test, with Welch’s correction where appropriate, or a Mann–Whitney test as indicated. Statistical significance is expressed as follows: *P < 0.05, **P < 0.01, ***P < 0.001.

2.11. Ethics statement

This work was carried out in accordance with regulations of The Animals (Scientific Procedures) Act 1986. All procedures were approved by the United Kingdom Home Office and carried out under the Home Office project licence PPL 70/7116.

3. Results

3.1. Construction of a VACV strain WR lacking the innate immunomodulatory genes N1L, C6L and K7R

To construct a virus lacking N1L, C6L, and K7R, C6L was deleted from a virus already lacking N1L (vΔN1, [17]) by transient dominant selection (see methods) yielding vΔΔ, followed by the removal of K7R yielding vΔΔΔ. As controls, a revertant virus where the deleted gene was re-inserted back into its natural locus was constructed at each stage (Fig. 1a). Deletion of C6L and K7R was confirmed by PCR analysis of proteinase K-treated lysates of infected BSC-1 cells using primers specific for these genes in addition to N1L and A49R as a control (Fig. 1b). The phenotype of the resulting recombinant viruses was confirmed at the protein level by immunoblotting of lysates from infected BSC-1 cells using antisera against N1, C6 and K7, as well as a monoclonal antibody against VACV protein D8 as an infection control (Fig. 1c). Proteins N1, K7 and C6 are each non-essential for virus replication or spread in cell culture [17–19] and measurement of the plaque size of mutants lacking 2 or 3 of these genes confirmed that deletion of these genes in combination did not affect viral spread in BSC-1 cells (Fig. 1d).

3.2. Deletion of N1L, C6L and K7R in combination attenuates the virus sequentially in murine intradermal and intranasal models of infection

The N1L [17,35], C6L [18] and K7R [19] single deletion viruses are attenuated in both the i.d. and i.n. models of murine infection.

![Fig. 1. Construction of a VACV strain WR lacking three innate immunomodulators. (a) Schematic representation of the order in which the C6L and K7R genes were removed from a virus already lacking N1L (vΔN1). Revertant viruses were constructed at each stage as controls. (b) PCR analysis of proteinase K-treated lysates of BSC-1 cells infected with the indicated viruses for 16 h at 2 p.f.u. per cell using primers specific for N1L, C6L, K7R and A49R. (c) Immunoblot analysis of BSC-1 cells infected for 16 h with the indicated viruses at 2 p.f.u. per cell. Lysates were analysed by SDS-PAGE and immunoblotted using monoclonal antibodies against α-tubulin and D8 or with polyclonal antisera against N1, C6 and K7. Molecular mass markers are indicated on the right (kDa). (d) Monolayers of BSC-1 cells were infected with the indicated viruses for 72 h. Cells were stained with crystal violet and the size of 20 plaques was measured using Axiovision acquisition software and a Zeiss AxioVert.A1 inverted microscope. Results are expressed as the mean plaque radius ± SD. Data are representative of at least 2 independent experiments.](image-url)
highlighting their importance as virulence factors. When compared side-by-side in the i.d. model, the level of attenuation was found to be similar amongst the three single deletion viruses (Suppl. Fig. 1a). In contrast, a virus lacking both N1 and C6 (vDD) was significantly more attenuated than vDN1, and a virus lacking all three immunodulators (vDDD) was attenuated further still (Fig. 2a), indicating that the roles of these innate inhibitors in vivo is non-redundant. The double deletion revertant (vDDR) and the triple gene deletion revertant (vDDD) control viruses behaved as expected, demonstrating that the observed attenuation phenotypes were due to specific genes deletions and not mutations elsewhere in the viral genome (Suppl. Fig. 1b). Similar results were obtained in the i.n. model of infection where deletion of C6 and K7 again led to sequential attenuation of the virus, as indicated by reduced weight loss (Fig. 2b) and fewer signs of illness (Fig. 2c).

3.3. Deletion of N1L, C6L and K7R in combination does not enhance vaccine potency

To determine whether the double and triple gene deletion viruses have improved vaccine potency compared with the N1 single deletion virus, mice were vaccinated i.d. and challenged i.n. one month later with a lethal dose of wild-type VACV WR. As reported [10], single deletion of N1 provided the mice with better protection against challenge, indicated by significantly less weight loss over a period of 10 days (Fig. 3a). However, vΔΔ provided less protection...
than both vΔN1 and vWT (although this did not reach statistical significance when compared to the WT virus on any one day) and vΔΔΔ provided significantly less protection again (Fig. 3a). Similar results were observed following challenge of mice that were vaccinated i.n. (Fig. 3b). When compared head-to-head each of the single deletion viruses enhanced vaccine potency to a similar degree (Suppl. Fig. 2a) and the revertant control viruses behaved as expected in challenge experiments (Suppl. Fig. 2b).

3.4. The double and triple gene deletion viruses induce lower CTL responses

To understand why vaccination with vΔΔ or vΔΔΔ afforded less protection than vAN1, CD8+ T cells responses one month post-i.d. vaccination were analysed. To measure the cytolytic activity of VACV-specific T cells a chromium release cytotoxicity assay was performed. The specific cytolytic activity of T cells from vΔN1-vaccinated mice was significantly higher than that from vWT-vaccinated animals (Fig. 4a), corroborating recently published findings [10]. Conversely, significantly lower VACV-specific cytolytic activity of T cells was measured in vΔΔ- or vΔΔΔ-vaccinated mice. Interestingly, no significant difference in cytolytic activity was observed between vΔΔ and vΔΔΔ.

The release of cytokines by splenic CD8+ T cells that were stimulated ex vivo with VACV peptides was also analysed by intracellular cytokine staining. In agreement with data published recently [10], splenic CD8+ T cells from vAN1-vaccinated mice secreted enhanced levels of IFNγ (Fig. 4b) and TNFα (Fig. 4c) following stimulation than cells from vWT-vaccinated mice. In contrast, splenic CD8+ T cells from both vΔΔ- and vΔΔΔ-vaccinated mice secreted significantly less cytokines. Again, no significant difference was observed between the double and triple gene deletion viruses.

3.5. Double and triple gene deletion viruses induce lower neutralising antibody titres

The poorer immunogenicity of the double and triple gene deletion viruses might also be due to altered antibody responses. To investigate this possibility, sera were collected from mice one month post-i.d. vaccination and the VACV-specific antibody titres and VACV-specific neutralising titres were measured by ELISA and plaque reduction neutralisation respectively. The titre of VACV-specific antibodies measured by ELISA was not different between the groups of vaccinated mice and good antibody levels were induced in all cases (Fig. 5a). The same was not true, however, when the titre of neutralising serum antibodies was measured by plaque reduction neutralisation assay. In this case the ND50 of sera from both the vΔΔ- and vΔΔΔ-vaccinated mice was significantly lower than that from both vWT and vAN1-vaccinated mice, although there was no significant difference between the double and triple gene deletion viruses (Fig. 5b).

4. Discussion

Inducing a robust innate immune response is an important step to designing an immunogenic vaccine and this is often achieved by
the addition of a vaccine adjuvant. However, a full understanding of how the innate immune system impacts immune memory is lacking and would greatly enhance our ability to rationally design vaccines with enhanced immunogenicity profiles. VACV-based vectors are popular candidates, however their genomes still encode proteins with a known role in dampening the host innate immune response, which may negatively impact their potential use as vaccine vectors. Indeed, the deletion of numerous VACV immunomodulatory genes has been shown to enhance immunogenicity including the chemokine-binding protein A41 [21,32], the IL-1β-binding protein B15 [21,36], the inhibitor of MHC class II antigen presentation A35 [37], the IL-18-binding protein C12 [38], the type I (B18) and type II (B8) IFN-binding proteins [39], the IRF3/7 inhibitor C6 [11,12], the NF-κB inhibitor and anti-apoptotic protein N1 I (B18) and type II (B8) IFN-binding proteins [39], the IRF3/7 inhibitor K7 (Fig. 2) they may have generated lower antigen levels and/or been cleared more quickly by the host immune system and hence induced a weaker adaptive response. The importance of antigen availability for the formation of CD8+ T cell-dendritic cell interaction kinetics and the ensuing memory response was demonstrated recently [41]. Of further interest, the inferior CD8+ T cell responses and neutralising antibody titres observed with vΔΔ and vAAAA were not significantly different between these two viruses, however vAAAΔ provided worse protection than vAAA in the challenge studies (Fig. 3). These data may indicate that other aspects of immune memory such as CD4+ T cells, or the recently identified memory NK cells [42] may play an important role in determining vaccine efficacy of VACV. Whether equivalent protection to WT or vAAA1 vaccination could be achieved by increasing the vaccination dose of vAAA and vAAAA warrants further investigation.

A recent study using an MVA vector expressing HIV-1 antigens (MVA-B) in the context of a DNA prime/MVA boost regime found that the deletion of C6L and K7R in combination enhanced the magnitude and quality of HIV-1-specific CD4+ and CD8+ T cell responses in mice, as well as Env antibody levels compared to the parental MVA-B vector and MVA-B lacking C6L alone [13]. These data demonstrate that in the context of a non-replicating strain of VACV, the deletion of more than one immunomodulatory gene may be beneficial. What is not clear from this study, however, is whether these memory responses would have been achieved with the deletion of K7R alone, because an MVA-B K7R single deletion was not included. Furthermore, whether these correlates of protection will translate to protection in an in vivo challenge model remains to be determined. Another recent study, also based on an MVA vector expressing HIV-1 antigens, found enhanced HIV-specific CD4+ and CD8+ T cell responses as well as Env-specific antibody responses in rhesus macaques with a vector lacking 4 immunomodulatory proteins [20]. However again this vector was not compared to single gene deletions and protection was not determined by a challenge experiment.

Mounting evidence indicates an important role for type I IFN [43,44] in vaccine immunogenicity and each of the proteins selected for this study inhibits type I IFN production. Furthermore, the importance of NF-κB in generating robust memory immune responses was demonstrated recently for N1, an inhibitor of NF-κB and apoptosis. By vaccinating mice with viruses encoding N1 mutants that were competent for only one of these functions it was demonstrated that the anti-NF-κB activity of N1 was important for the enhanced protection observed with vAAA1, with no apparent contribution of its anti-apoptotic function [35]. These types of studies demonstrate how viruses lacking innate immunomodulators can be utilised as tools to further our understanding of the relationship between innate immunity and immune memory, which will be important for future vaccine design.
Fig. 5. Humoral responses one month post-vaccination. Antibody responses of C57BL/6 mice (n = 5) were measured one month post-vaccination with 10^6 p.f.u. of the indicated viruses in both ear pinnae. (a) Serum antibody end-point titres against VACV proteins were determined by ELISA. End-point titres were defined as the reciprocal serum dilution giving twice the optical density obtained from BSA. (b) The neutralisation capacity of antibodies in the serum was assessed by plaque-reduction neutralisation against VACV strain WR intracellular mature virus. The median value for each population is represented by a horizontal black bar. Statistical analyses were performed using the Student’s t-test. *P < 0.01, ns: not significant. Experiments were conducted at least 3 times and representative data are shown.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

This work was supported by Grants from the U.K. Medical Research Council and the Wellcome Trust. GLS is a Wellcome Trust Principal Research Fellow.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.08.002.

References

[1] Smith GL, Mackett M, Moss B. Recombinant vaccinia viruses as new live vaccines. Biotechnol Gen Eng Rev 1984;2:383–407.
[2] Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccin 2011;10:1221–40.
[3] Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004;101:4590–5.
[4] Gomez CE, Najera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 2008;8:97–120.
[5] Gilbert SC. Clinical development of modified vaccinia virus ankara vaccines. Vaccine 2013;31:4241–6.
[6] Smith GL, Benfield CT, de Motes C Maluquer, Mazzon M, Ember SW, Ferguson BJ, et al. Vaccinia virus gene A36R encodes a Mr 43–50 K protein on the surface of extracellular enveloped virus. Virology 2014;488:3092–102.
[7] Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vacc Immunother 2014;10:2235–44.
[8] Ren H, Ferguson BJ, de Motes C Maluquer, Sumner RP, Harman LE, Smith GL. Enhancement of CD8+ T-cell memory by removal of a vaccinia virus nuclear factor-kappaB inhibitor. Immunology 2015;145:34–49.
[9] Sumner RP, Ren H, Smith GL. Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol 2013;94:1121–6.
[10] Garcia-Arriaza J, Najera JL, Gomez CE, Tewabe N, Sorzano CO, Calandra T, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE 2011;6:e24244.
[11] Garcia-Arriaza J, Arana P, Gomez CE, Sorzano CO, Esteban M. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (CGL and K7R) blocking interferon signaling pathways. PLoS ONE 2013;8:e66094.
[12] Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, Chen RA, et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveals a Bcl-2-like anti-apoptotic protein. J Gen Virol 2007;88:1656–66.
[13] Kalverda AP, Thompson CS, Vogel A, Schroder M, Bowie AG, Khan AR, et al. Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX2. J Mol Biol 2009;385:843–53.
[14] Graham SC, Bahar MW, Cooray S, Chen RA, Whalen DM, Abrescia NG, et al. Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 2008;4:e1000128.
[15] Bartlett N, Symons JA, Tscharke DC, Smith GL. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 2002;83:1965–76.
[16] Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, Bourke NM, et al. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 2011;7:e1002247.
[17] Benfield CT, Ren H, Lucas SJ, Bahsoun B, Smith GL. Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J Gen Virol 2013;94:1647–57.
[18] Gervais DA, O’Meara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, et al. Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 2012;86:12005–15.
[19] Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS ONE 2010;5:e12395.
[20] Falsouger FG, Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus infectivity. J Virol 1987;62:1849–54.
[21] Parkinson JL, Smith GL. Vaccinia virus gene A36R encodes a Mr43–50 K protein on the surface of extracellular enveloped virus. Virology 1994;204:376–9.
[22] Schroder M, Baran M, Bowie AG. Viral targeting of DEAF box protein 3 reveals its role in TBK1/IRKeepsin-mediated IRF activation. EMBO J 2008;27:2147–57.
[23] Ferguson BJ, Benfield CT, Ren H, Lee VH, Frazer GL, Strnadova P, et al. Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol 2013;94:2070–81.
[24] Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 1990;71:2761–7.
[25] Alcami A, Smith GL. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 1992;71:153–67.
[26] Tscharke DC, Smith GL. A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 1999;80:2751–5.
[27] Tscharke DC, Reading PC, Smith GL. Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 2002;83:1977–86.
[28] Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM, et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005;201:95–104.
[29] Tscharke DC, Woo WP, Sakala GC, Sidney J, Sette A, Moss DJ, et al. Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 2006;80:6318–23.
[30] Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 2006;87:29–38.
[33] Law M, Putz MM, Smith GL. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 2005;86:991–1000.

[34] Putz MM, Midgley CM, Law M, Smith GL. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 2006;12:1310–5.

[35] de Motes C Maluquer, Cooray S, Ren H, Almeida GM, McGourty K, Bahar MW, et al. Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 2011;7:e1002430.

[36] Staib C, Kesling S, Erle V, Sutter G. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 2005;86:1997–2006.

[37] Rehm KE, Roper RL. Deletion of the A35 gene from modified vaccinia virus ankara increases immunogenicity and isotype switching. Vaccine 2011;29:3276–83.

[38] Falivene J, Zajac MP Del Medico, Pascutti MF, Rodriguez AM, Maeto C, Perdiguerò B, et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS ONE 2012;7:e32229.

[39] Gomez CE, Perdiguerò B, Najera JL, Sorzano CO, Jimenez V, Gonzalez-Sanz R, et al. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 2012;86:5026–38.

[40] Perdiguerò B, Gomez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, et al. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS ONE 2013;8:e74831.

[41] Henrickson SE, Perro M, Loughhead SM, Semnan B, Stutte S, Quigley M, et al. Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity 2013;39:496–507.

[42] Gillard GO, Bivas-Benita M, Hovav AH, Grandpre LE, Panas MW, Seaman MS, et al. Thyl+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. PLoS Pathog 2011;7:e1002141.

[43] Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002;14:432–6.

[44] Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology 2011;132:466–74.